Psychiatric Medication Management Denied: How to Appeal

Psychiatric Medication Management Denied: How to Appeal

Psychiatric medication management — the regular appointments between a patient and their psychiatrist to monitor, adjust, and optimize psychiatric medications — is one of the most misunderstood and underreimbursed services in all of mental healthcare.

When insurance denies these visits, the consequences can be severe. Psychiatric medications often require ongoing monitoring for efficacy, side effects, and safety. Patients taking mood stabilizers, antipsychotics, or other psychiatric medications can face serious medical risks without regular clinical oversight. Yet insurance companies routinely deny medication management claims as "not medically necessary" — particularly once a patient is considered "stable."

This guide explains why medication management is denied, what your legal rights are, and exactly how to fight these denials.

What Is Psychiatric Medication Management?

Psychiatric medication management refers to clinical visits — primarily with psychiatrists, but also with psychiatric nurse practitioners (PMHNPs) and, in some states, trained psychologists — focused on:

• Evaluating medication efficacy and adjusting doses
• Monitoring for side effects (including metabolic effects of antipsychotics, cardiac effects of stimulants, lithium toxicity, etc.)
• Addressing medication adherence issues
• Managing polypharmacy and drug interactions
• Conducting required monitoring labs (e.g., lithium levels, CBC for clozapine, thyroid function on lithium)

Billing codes used include:

• 99213 / 99214 / 99215: Office or outpatient E/M visits (most common for medication management)
• 90833 / 90836 / 90838: Psychotherapy add-on codes when psychotherapy is also provided in the same visit
• 99212: Brief E/M visits (low complexity, rarely appropriate for psychiatric medication management)

Why Medication Management Claims Are Denied

"Patient Is Stable — No Medical Necessity"

The most common and most infuriating denial reason. An insurer determines that because a patient's symptoms are currently controlled, ongoing medication management visits are not necessary.

This reasoning fundamentally misunderstands psychiatric pharmacotherapy. Psychiatric stability is actively maintained — it does not persist automatically without clinical oversight. Stopping or failing to monitor medications for conditions like bipolar disorder, schizophrenia, or severe OCD often results in relapse — relapse that is far more expensive to treat than the prevented visits.

The American Psychiatric Association explicitly recommends continued follow-up during stable phases of treatment for most psychiatric conditions. These recommendations should be cited in your appeal.

Frequency Denials

Insurers may approve some medication management visits but deny visits they deem too frequent. For example:

• Approving quarterly visits but denying monthly visits for a patient whose medication requires close monitoring
• Denying follow-up visits after a medication change that occurred within a short window

Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Not Obtained

Many plans require prior authorization for psychiatric medication management beyond an initial number of visits. If the prescriber's office did not obtain or renew authorization on time, claims are retroactively denied.

Coding Issues

Common coding-related denials:

• Psychotherapy add-on denied: Insurer argues the psychotherapy component (90833) was not sufficiently documented as a separate service from the E/M visit
• Level of service mismatch: Billing a 99214 when documentation supports only a 99213
• Diagnosis code mismatch: Diagnosis on the claim does not match the diagnosis in the chart or prior authorization

Provider Credentialing Issues

If a PMHNP's supervising physician is not listed correctly, or if the provider recently joined a group practice and their NPI has not been updated with the insurer, claims will be denied on credentialing grounds.

Your Legal Rights

Mental Health Parity Act (MHPAEA) Explained" class="auto-link">mhpaea-and-medication-management">MHPAEA and Medication Management

MHPAEA requires that prior authorization and medical necessity criteria for psychiatric medication management be no more restrictive than for comparable medical services — such as cardiology follow-up visits for patients on heart medications.

Consider: would an insurer deny monthly cardiology follow-ups for a patient on warfarin because they are "stable"? Almost certainly not. Applying a "stable = no medical necessity" standard to psychiatric medication management while not applying it to comparable medical services is a clear parity violation.

This is one of the strongest parity arguments available for medication management denials.

Step Therapy / Fail-First Policies

Some insurers require patients to try (and fail on) less expensive medications before approving coverage for prescribed medications. These step therapy protocols for psychiatric medications are increasingly scrutinized under MHPAEA. Many states have enacted "step therapy override" laws that allow providers to bypass these protocols when clinically appropriate.

As of 2024, at least 30 states have enacted step therapy reform laws. Check your state's requirements — if the insurer is requiring you to use a medication that is clinically contraindicated, you may have grounds to override the step therapy requirement.

How to Appeal a Medication Management Denial

Step 1: Determine the Denial Type

Is this:

• A medical necessity denial for a specific visit?
• A prior authorization denial for ongoing visits?
• A coding or administrative denial?
• A step therapy denial for a specific medication?

The appeal strategy differs by type.

Step 2: Gather Clinical Documentation

For medical necessity denials, compile documentation demonstrating:

• The specific psychiatric condition being managed and its severity
• Current medications, doses, and rationale for each
• Why the current visit frequency is clinically necessary (not just routine)
• Any monitoring requirements associated with specific medications (e.g., monthly labs for clozapine, quarterly lithium levels)
• History of what happened when monitoring was reduced or interrupted (if applicable)
• Current symptom status, functional impairment, and risk factors

Step 3: Cite APA Practice Guidelines

The APA publishes clinical practice guidelines for most major psychiatric conditions. These guidelines include recommendations for follow-up frequency during maintenance treatment. For example:

• APA guidelines for bipolar disorder recommend ongoing monitoring even during euthymic periods
• APA guidelines for schizophrenia recommend regular medication management visits to monitor for tardive dyskinesia, metabolic effects, and relapse risk
• APA guidelines for major depressive disorder recommend follow-up visits to assess response and adjust treatment

Citing these guidelines directly in your appeal creates a strong evidence-based argument that the insurer's "not medically necessary" determination conflicts with established clinical standards.

Step 4: Make the Parity Argument

If the insurer is applying a "stable patient" standard to psychiatric medication management that it does not apply to comparable medical services, document this in your appeal:

"Under the Mental Health Parity and Addiction Equity Act (42 U.S.C. § 300gg-26), [Insurer Name] is required to apply medical necessity criteria for mental health services no more stringently than for comparable medical/surgical services. The determination that ongoing psychiatric medication management is not medically necessary because the patient is 'stable' would not be applied to a patient receiving ongoing medication management for a chronic medical condition such as hypertension or hypothyroidism. This denial therefore constitutes a non-quantitative treatment limitation (NQTL) that is more restrictive for mental health benefits than for medical/surgical benefits, in violation of MHPAEA."

Step 5: Request a Peer-to-Peer Review

For medication management denials, a peer-to-peer with the insurer's reviewing physician — ideally a psychiatrist — can be decisive. Be prepared to explain:

• The specific monitoring requirements for the medications prescribed
• Why reduced visit frequency would increase clinical risk
• The expected outcome if visits are reduced (e.g., risk of lithium toxicity without quarterly levels, risk of tardive dyskinesia without regular AIMS assessments)

Step 6: Address Coding Issues

If the denial involves the psychotherapy add-on (90833), ensure your documentation includes:

• A separate note section documenting the psychotherapy portion of the visit
• Time spent on psychotherapy vs. medication management
• The therapeutic modality used (CBT, supportive therapy, motivational interviewing, etc.)

If the denial involves level of service, review your documentation against the AMA's MDM (Medical Decision Making) criteria and time-based criteria for the level billed.

For Patients: Your Role in the Appeal

When your medication management visits are denied, you have independent appeal rights. A patient-authored appeal letter that describes:

• How your psychiatric medications have improved your ability to function
• What happened in the past when visits were less frequent or medications were not properly monitored
• The specific risk to your health and safety if coverage is denied

...can carry significant weight alongside your psychiatrist's clinical appeal.

ClaimBack offers a free tool to help patients write professional, personalized appeal letters for psychiatric medication management denials.

Generate your free medication management appeal letter →

For Psychiatrists: Managing Medication Management Denials at Scale

Psychiatrists who accept insurance face medication management denials regularly. Key prevention strategies:

1. Document the "why" behind every visit: Do not just document current symptoms — document why this level of monitoring frequency is clinically necessary
2. Flag monitoring requirements in your notes: For medications requiring specific lab monitoring, make the monitoring rationale explicit
3. Track prior auth expiration dates: Set systematic reminders for authorization renewals
4. Document psychotherapy separately: If billing the add-on, ensure the psychotherapy portion of the visit is clearly documented

ClaimBack is designed specifically to help psychiatrists generate tailored appeals for medication management denials — pulling from clinical notes and the specific denial criteria to produce letters that address the insurer's arguments point by point.

Try ClaimBack for psychiatric practices →

Key Takeaways

• "Stable patient" is not a valid reason to deny psychiatric medication management under MHPAEA
• Medication monitoring requirements (for lithium, clozapine, antipsychotics, etc.) provide strong medical necessity arguments
• APA practice guidelines are powerful evidence in medication management appeals
• Peer-to-peer reviews are highly effective, especially with a psychiatrist reviewer
• Step therapy protocols for psychiatric medications may be overridable in 30+ states

Medication management denials are winnable. The clinical rationale is strong, the legal protections are clear, and the data supports continued treatment. With the right appeal strategy, most of these denials can be reversed.

Take Action Today

Psychiatrists and PMHNPs: Streamline your medication management appeal process with ClaimBack's AI-powered provider portal.

Sign up for ClaimBack for providers →

Patients: Get a free, personalized appeal letter for your denied medication management visits.

Start your free appeal at ClaimBack →